Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations

We have previously identified sitravatinib as a potent inhibitor of FLT3, capable of overcoming resistance to gilteritinib in the treatment of acute myeloid leukemia (AML). The combination of venetoclax and FLT3 inhibitors gilteritinib and quizartinib has shown promising results in reducing leukemia...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jie Yang, Yvyin Zhang, Qingshan Li, Peihong Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-09-01
coleção:	Translational Oncology
Assuntos:	FLT3-ITD mutation BCL-2 inhibitor Venetoclax Sitravatinib Synergistic effect
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1936523325001986
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!